Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Legend Biotech (LEGN) Interest Expenses (2019 - 2025)

Legend Biotech filings provide 7 years of Interest Expenses readings, the most recent being -$5.5 million for Q4 2025.

  • On a quarterly basis, Interest Expenses fell 5.77% to -$5.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$21.4 million, a 99.93% decrease, with the full-year FY2025 number at -$21.4 million, up 0.93% from a year prior.
  • Interest Expenses hit -$5.5 million in Q4 2025 for Legend Biotech, up from -$5.6 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $5.5 million in Q1 2024 to a low of -$5.7 million in Q3 2023.
  • Median Interest Expenses over the past 5 years was -$5.0 million (2022), compared with a mean of -$2.9 million.
  • Biggest five-year swings in Interest Expenses: soared 2515.79% in 2022 and later plummeted 89247.08% in 2024.
  • Legend Biotech's Interest Expenses stood at -$602000.0 in 2021, then crashed by 707.48% to -$4.9 million in 2022, then skyrocketed by 99.88% to -$5820.0 in 2023, then plummeted by 89247.08% to -$5.2 million in 2024, then fell by 5.77% to -$5.5 million in 2025.
  • The last three reported values for Interest Expenses were -$5.5 million (Q4 2025), -$5.6 million (Q3 2025), and -$5.2 million (Q2 2025) per Business Quant data.